company background image
RGT logo

Argent BioPharma LSE:RGT Stock Report

Last Price

UK£0.065

Market Cap

UK£4.2m

7D

0%

1Y

-76.4%

Updated

23 Dec, 2024

Data

Company Financials

RGT Stock Overview

A multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. More details

RGT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Argent BioPharma Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Argent BioPharma
Historical stock prices
Current Share PriceAU$0.065
52 Week HighAU$0.30
52 Week LowAU$0.05
Beta1.1
1 Month Change-59.38%
3 Month Change-60.00%
1 Year Change-76.36%
3 Year Change-99.69%
5 Year Changen/a
Change since IPO-99.73%

Recent News & Updates

Recent updates

Shareholder Returns

RGTGB PharmaceuticalsGB Market
7D0%-0.4%-1.9%
1Y-76.4%-2.1%2.6%

Return vs Industry: RGT underperformed the UK Pharmaceuticals industry which returned -3.5% over the past year.

Return vs Market: RGT underperformed the UK Market which returned 2.4% over the past year.

Price Volatility

Is RGT's price volatile compared to industry and market?
RGT volatility
RGT Average Weekly Movement23.1%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: RGT's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: RGT's weekly volatility has increased from 16% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aRoby Zomerargentbiopharma.com

Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment.

Argent BioPharma Limited Fundamentals Summary

How do Argent BioPharma's earnings and revenue compare to its market cap?
RGT fundamental statistics
Market capUK£4.19m
Earnings (TTM)-UK£8.74m
Revenue (TTM)UK£444.05k

9.4x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGT income statement (TTM)
RevenueAU$891.08k
Cost of RevenueAU$1.20m
Gross Profit-AU$304.15k
Other ExpensesAU$17.23m
Earnings-AU$17.53m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin-34.13%
Net Profit Margin-1,967.34%
Debt/Equity Ratio-149.0%

How did RGT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:43
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Argent BioPharma Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Salvatore Gaetano VerdolivaCanaccord Genuity
Robin DavisonCapital Network by Proactive Investors
Maxim JacobsEdison Investment Research